Brief: DocGo Q2 Revenue USD 80.4 Million Vs. IBES Estimate USD 77.6 Million

DocGo

07/08/2025 21:22

Overview

DocGo Q2 2025 revenue falls 51% yr/yr but beats analyst expectations, per LSEG data

Adjusted EBITDA loss for Q2 beats estimates, per LSEG data

Company reiterates 2025 revenue and adjusted EBITDA guidance

Outlook

DocGo expects full-year 2025 revenue of $300-$330 mln

Company anticipates full-year 2025 adjusted EBITDA loss of $20-$30 mln

DocGo plans to enter more states in payer-provider vertical by 2026

Company expects increased revenue in medical transportation in H2 2025

Result Drivers

CASH BALANCE INCREASE - Total cash balance rose to $128.7 mln due to collections on migrant-related receivables, per CFO Norm Rosenberg

COST REDUCTION - Significant cuts to corporate overhead expected to save $10 mln annually, with further reductions planned

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$80.40 mln
$77.60 mln (7 Analysts)
Q2 Net Income
-$13.30 mln
Q2 Adjusted EBITDA
Beat
-$6.10 mln
-$7.14 mln (7 Analysts)
Q2 Gross Margin
26.7%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for DocGo Inc is $3.00, about 53% above its August 6 closing price of $1.41

Press Release: ID:nBw8VrkQca

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)